|INVITED RESEARCH HIGHLIGHT
|Year : 2015 | Volume
| Issue : 5 | Page : 769-770
Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?
Giovanni Lughezzani, Nicoló Maria Buffi
Department of Urology, Istituto Clinico Humanitas, Rozzano, Italy
|Date of Web Publication||28-Apr-2015|
Department of Urology, Istituto Clinico Humanitas, Rozzano
Source of Support: None, Conflict of Interest: None
Prostate cancer (PCa) represents the most common malignancy in adult males with an estimated number of 280 000 newly diagnosed cases only in the United States in 2015.  Due to the introduction of PSA in clinical practice, the majority of the patients are currently diagnosed with organ-confined and sometimes indolent disease. However, a nonnegligible proportion of individuals are still diagnosed with locally-advanced tumors. In their recently published article, Bekelman et al.  focused on elderly patients with locally-advanced PCa in the attempt to determine the best treatment approach in this patient category, and concluded that, even in these individuals, androgen deprivation therapy (ADT) plus radiotherapy (RT) may confer a survival benefit relative to ADT alone. The importance of the current article resides in the fact that it focuses on a patient population that has not been, or has been only scarcely, included in previous studies on the same topic.
|How to cite this article:|
Lughezzani G, Buffi NM. Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?. Asian J Androl 2015;17:769-70
|How to cite this URL:|
Lughezzani G, Buffi NM. Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?. Asian J Androl [serial online] 2015 [cited 2021 Oct 25];17:769-70. Available from: https://www.ajandrology.com/text.asp?2015/17/5/769/151394 - DOI: 10.4103/1008-682X.151394
The survival benefit of RT plus ADT versus ADT alone in patients with locally-advanced PCa has been recently demonstrated by two randomized controlled trials (RCTs). , Specifically, Widmark et al. recruited 875 patients from 47 Scandinavian centers who were randomized to receive either ADT or ADT plus RT.  Inclusion criteria for this study were age ≤75 and a life expectancy ≥10 years. According to this trial, the 10-year cancer-specific mortality rate was 23.9% in the ADT group relative to 11.9% in the ADT plus RT group. The same study demonstrated a slightly higher, but still acceptable, proportion of urinary, rectal and sexual problems in the latter group of patients. Similarly, Warde et al.  evaluated the outcomes of 1205 individuals randomly assigned to be treated either with ADT or with ADT plus RT. Patients aged ≤80 years and with an Eastern Cooperative Oncology Group performance status between 0 and 2 were included. At 7 years, an 8% overall survival benefit was observed in the ADT plus RT group relative to patients receiving ADT alone. As in the previous study, gastrointestinal toxicities were most frequent in the ADT plus RT group.
While both of these RCTs represent well-designed and well-conducted studies supporting the effectiveness of ADT plus RT in locally-advanced PCa, their strict inclusion criteria may limit the applicability of their findings to the general population. To overcome this issue and provide further evidences supporting the role of ADT plus RT in patients with high-risk PCa, Bekelman et al.  used a population-based (SEER-Medicare) dataset to extrapolate three different groups of patients with locally-advanced PCa diagnosed between 1995 and 2007: (1) the RCT cohort (n = 12.924), consisting of patients selected according to the same inclusion criteria defined by the two previously cited studies; (2) the elderly cohort (n = 14.340), consisting of men aged between 76 and 85 years with locally-advanced PCa; (3) the screen-detected cohort (n = 4277), consisting of patients aged between 65 and 85 years with high-risk clinically undetectable disease. Besides standard survival analysis, the authors also adopted two statistical methodologies, namely the propensity score approach and instrumental variable analysis in order to adjust for possible confounders. In all of the three scenarios (unadjusted, propensity-score and instrumental variable adjusted), ADT plus RT resulted in a significant increase both in cancer-specific and overall mortality rates as compared to ADT alone. Interestingly, the survival benefit was observed not only in the RCT cohort, but also in the elderly and in the screen-detected ones. In consequence, this study provides evidences to expand the indications for ADT plus RT also to these patients. This is even more important when considering that, despite the potential survival benefits, older patients with locally-advanced PCa are less likely to receive local therapies relative to their younger counterparts. 
However, while the population-based nature of this study may support the generalizability of its findings, it also represents a potential limitation that should be taken into account when interpreting the results. As correctly stated by the authors, several important data, such as total PSA and radiation dose/field, were missing. The retrospective nature of the dataset along with the risk of a misclassification bias also represents a limitation. In addition, no information was provided regarding the toxicities of ADT plus RT versus ADT alone and whether differences in the rate of side effects existed between the three groups. Finally, the oncological outcomes and morbidities of ADT plus RT in locally-advanced PCa should also be compared to those of radical prostatectomy with or without adjuvant RT, especially in carefully selected patients with a life expectancy ≥10 years.
In conclusion, the study by Bekelman et al.  adds important evidences regarding the oncological effectiveness of ADT plus RT relative to ADT alone in locally-advanced PCa even in older individuals. However, the clinical applicability of their findings should be further corroborated by prospective randomized trials focusing on this patient category.
| Competing Interests|| |
The author declares no competing interests.
| References|| |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin
2015; 65: 5-29.
Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, et al.
Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol
2015; 33: 716-22.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, et al.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet
2009; 373: 301-8.
Warde P, Mason M, Ding K, Kirkbride P, Brundage M, et al.
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet
2011; 378: 2104-11.
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol
2011; 29: 235-41.